We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mobile Suitcase Laboratory Rapid Detects Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 15 Jun 2016
Leishmania donovani (LD) is a protozoan parasite transmitted to humans from sand flies, which causes Visceral Leishmaniasis (VL) and currently, the diagnosis is based on presence of the anti-LD antibodies and clinical symptoms.

Molecular diagnosis would require real-time polymerase chain reaction (qPCR), which is not easy to implement at field settings; however a recombinase polymerase amplification (RPA) assay has been developed and tested for the detection of LD.

Scientists at the Georg-August-University (Gottingen, Germany) and their colleagues tested a total of 48 archived DNA samples from VL patients, asymptomatic individuals and post-kala-azar dermal leishmaniasis (PKDL) patients were tested by both RPA and real-time PCR assays. More...
To determine the specificity of the assay, the archived DNA samples including 35 endemic healthy controls, five non-endemic healthy controls and disease controls including six malaria cases and two tuberculosis cases were also investigated.

All VL, PKDL and asymptomatic cases were positive for LD DNA by realtime PCR, while controls (healthy and disease) were negative for rK39, direct antiglobulin test (DAT) and LD DNA by real-time PCR. Quantitative detection of Leishmania DNA was performed on a CFX96 real time detection system (Bio-Rad, Hercules CA, USA). Two mobile suitcase laboratories were constructed to have separate workspaces for nucleic acid extraction and detection in order to avoid any possible contamination. Blood samples were collected from seven patients hospitalized at the Surya Kanta Kala-azar Research Center, and nucleic acid was extracted from whole blood and RPA test was performed in the field.

The LD RPA assay detected equivalent to one LD genomic DNA. The assay was performed at constant temperature of 42 °C in 15 minutes. The RPA assay also detected other Leishmania species (L. major, L. aethiopica and L. infantum), but did not identify nucleic acid of other pathogens. Forty-eight samples from VL, asymptomatic and post-kala-azar dermal leishmaniasis subjects were detected positive and 48 LD-negative samples were negative by both LD RPA and real-time PCR assays, which indicates 100 % agreement. The suitcase laboratory was successfully operated at the local hospital by using a solar-powered battery. DNA extraction was performed by a novel magnetic bead based method (SpeedXtract, Qiagen, Hilden, Germany), in which a simple fast lysis protocol was applied. Moreover, all reagents were cold-chain independent.

The authors concluded that the use of a mobile suitcase laboratory is advantageous for rapid, sensitive and specific detection of LD using SpeedXtract and RPA assay, especially, at low resource settings such as Bangladesh and could contribute to VL control and elimination program. The study was published in the May 2016 issue of the journal Parasites &Vectors.

Related Links:
Georg-August-University
Bio-Rad
Qiagen

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.